EN DE
Watch Medplus Health Services Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medplus Health Services Limited (MEDPLUS) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Medplus Health Services Limited stock ₹708, price ₹619, upside +14.4%, quality 59 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE804L01022

MH Medplus Health Services Limited logo Some data Nov 11, 2026

Medplus Health Services Limited

MEDPLUS · NSE

Solid company, but only slightly cheap (13% below fair value) and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹707.67 · Undervalued 
Healthy Growth (revenue 5y +17.6 %/yr in INR) 
Low debt 
Generates free cash flow 
Revenue last quarter +23% vs. a year ago. 
Quality 59/100 
Thin margins · 2.8% net margin (TTM) 
Mixed vs. peers (7/13) 
Some data 
Falling price (downtrend) 
Narrow moat 37/100
Watch Medplus Health Services Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,290 ₹576.30 Fair Value ₹707.67 Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

59‑month range ₹576.30 – ₹1,290 · fair‑value band ₹518.24 – ₹919.98 · the ₹618.60 price screens below the ₹707.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Medplus Health Services in your weekly email

Every Wednesday you see whether Medplus Health Services is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India.

Show moreShow less

It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers.

The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres.

It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.

Stock analysis

Medplus Health Services Limited (MEDPLUS) currently trades at ₹618.60, while our model-based Fair Value estimate is ₹707.67, implying the stock looks roughly 13% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of ₹626.34 per share, and 6 of the 24 models we run sit above the ₹618.60 price.

Bear case: the Economic Profit group reads lowest at ₹202.62, and 18 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹518.24 (bear) to ₹919.98 (bull), the price of ₹618.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Medplus Health Services Limited reported revenue of ₹68.9B in FY2026 versus ₹37.8B in FY2022, a compound +16.2%/yr. Reported net income was ₹2.2B in FY2026, compounding +23.1%/yr from FY2022.

Key figures

Market cap ₹74.3B (≈ $788M) Small · P/E ratio 35.1 · P/S ratio 0.98 · EPS (TTM) ₹17.62 · Net margin 2.8% · Return on equity 10.8% · Return on assets (EBIT) 15.7% (5-year average) · Operating margin 5.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 35% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 23% fair-value upside, at 14%, MEDPLUS screens richer than that median.

Fair Value models

Bear ₹518.24 Fair Value ₹707.67 Bull ₹919.98
Price ₹618.60 · Upside +14.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹11.10 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹459.31 ₹746.85 ₹1,235 78
Growth DCF ₹446.61 ₹697.94 ₹1,054 78
Owner Earnings ₹355.91 ₹585.10 ₹940.65 75
All 24 models by family
DCF Models
FCF DCF ₹459.31 ₹746.85 ₹1,235 78
Owner Earnings ₹355.91 ₹585.10 ₹940.65 75
5Y Revenue Exit ₹349.61 ₹557.73 ₹839.69 72
5Y EBITDA Exit ₹478.77 ₹837.26 ₹1,300 74
5Y P/E Exit ₹363.45 ₹587.69 ₹848.45 70
10Y Revenue Exit ₹380.86 ₹581.82 ₹891.99 66
10Y EBITDA Exit ₹462.85 ₹763.12 ₹1,239 67
10Y P/E Exit ₹395.58 ₹601.25 ₹898.61 63
Earnings-Based
Graham-Dodd ₹124.31 ₹679.57 ₹942.60 63
Lynch FV ₹188.87 ₹269.82 ₹350.76 61
PEG = 1.0 ₹188.87 ₹269.82 ₹350.76 57
EPV ₹199.97 ₹219.59 ₹235.55 74
Multiples
P/E Multiple ₹287.91 ₹383.89 ₹479.86 63
P/S Multiple ₹233.07 ₹310.77 ₹388.46 58
P/B Multiple ₹645.10 ₹860.14 ₹1,075 55
EV/EBIT ₹264.25 ₹379.03 ₹493.81 65
EV/EBITDA ₹412.76 ₹577.04 ₹741.33 67
EV/Revenue ₹165.68 ₹271.00 ₹376.33 52
Asset-Based
NCAV (Graham) ₹6.12 ₹9.28 ₹11.60 54
Growth DCF
Growth DCF ₹446.61 ₹697.94 ₹1,054 78
Rev-Margin DCF ₹349.61 ₹554.73 ₹834.01 72
Economic Profit
Residual Income ₹134.29 ₹146.28 ₹170.65 71
ROIC Compounder ₹213.18 ₹258.96 ₹315.91 72
Growth Earnings
Growth-Adj P/E ₹275.21 ₹393.15 ₹511.10 67

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 49
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 64
Does it invest with discipline instead of growing at any price?
Low Volatility 84
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+25.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.4%
Dividend (yield on the price)0.0%
2026 sits 235% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +8.4% a year for the price and +8.3% for the forecasts.
Forecast 2027 (sales)+18.0%
Forecast 2028 (sales)+13.8%
Projected 2029 (sales)+12.3%
Projected 2030 (sales)+10.8%
Projected 2031 (sales)+9.4%

Watch MEDPLUS, get fair value alerts →

Compare Medplus Health Services Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 52 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside +14.4% · Below median
Profitability
Return on equity (12 months) 10.8% · Above median
Return on assets 5.6% · Above median
Net margin (12 months) 2.8% · Above median
Operating margin (12 months) 5.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 22.5% · Top 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (12 months) 35.1× · Priciest 25%
P/B 3.76× · Priciest 25%
P/S (12 months) 0.98× · Pricier than median
Price / free cash flow (fiscal year) 18.4× · Priciest 25%
EV/EBITDA 16.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)53 · sector 61
FUTURE (revenue growth)100 · sector 21
PAST (return on equity)43 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 53

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medplus Health Services Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medplus Health Services Limited Fair Value". https://www.fairvalue-calculator.com/stock/MEDPLUS

Frequently asked questions

Is Medplus Health Services Limited (MEDPLUS) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹707.67 versus a price of ₹618.60, about +14% upside (undervalued).
What is the fair value of MEDPLUS?
Our model-based fair value for Medplus Health Services Limited is ₹707.67 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹618.60.
What is the quality score of MEDPLUS?
Medplus Health Services Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medplus Health Services Limited (MEDPLUS)?
Our model-based price target is the fair value of ₹707.67 (as of Nov 11, 2026) from 24 valuation models. Cautious scenario ₹518.24, optimistic scenario ₹919.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Medplus Health Services Limited stock forecast for 2026?
Our models put fair value at ₹707.67, about +14% upside versus a price of ₹618.60 (undervalued). Cautious scenario ₹518.24, optimistic scenario ₹919.98. The calculation is refreshed regularly with new filings.
What is the revenue of Medplus Health Services Limited (MEDPLUS)?
Medplus Health Services Limited reported trailing-twelve-month revenue of about ₹76.0B (latest available figure, as of Nov 11, 2026).
What growth is priced into Medplus Health Services Limited (MEDPLUS)?
For today's price to be fair in a discounted-cash-flow model, Medplus Health Services Limited would have to grow free cash flow by 12.9 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 17.6 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of MEDPLUS use?
Our models discount Medplus Health Services Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.46, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medplus Health Services Limited that is +12.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Medplus Health Services Limited (MEDPLUS) delivered so far?
Over the past 5 years revenue at Medplus Health Services Limited grew 17.6 % a year. The price currently implies free-cash-flow growth of +12.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medplus Health Services Limited (MEDPLUS) growing?
The median revenue growth in the sector is +4.0 % a year. That is the yardstick for the growth priced into Medplus Health Services Limited (+12.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medplus Health Services Limited (MEDPLUS)?
The free-cash-flow yield on the price is 5.44 %: that much free cash flow Medplus Health Services Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medplus Health Services Limited (MEDPLUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medplus Health Services Limited it is ₹707.67 per share (as of Nov 11, 2026), against a price of ₹618.60. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Medplus Health Services Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, MEDPLUS trades below its calculated fair value: price ₹618.60, fair value ₹707.67, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDPLUS?
No. The price is what the market pays today (₹618.60); the fair value is what the company's own numbers justify (₹707.67). For Medplus Health Services Limited the two are ₹89.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medplus Health Services Limited worth?
The market values Medplus Health Services Limited at about ₹74.3B (market capitalisation, as of Nov 11, 2026). Per share that is ₹618.60; our models calculate a fair value of ₹707.67 per share.
What do the bullish and bearish scenarios say about MEDPLUS?
Our models span a range for Medplus Health Services Limited: cautious scenario ₹518.24, base ₹707.67, optimistic ₹919.98 per share (as of Nov 11, 2026, price ₹618.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDPLUS?
Medplus Health Services Limited trades at a price-to-earnings ratio of 35.1 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹707.67 is built from several models across several years. Median P/E at fiscal year-end, 5 fiscal years (2022 to 2026), reported earnings, FY2026 ex one-offs: 119.1. Other multiples: P/B 3.8, P/S 1.0, EV/EBITDA 16.3.
How solid is the balance sheet of Medplus Health Services Limited (MEDPLUS)?
Balance-sheet figures for Medplus Health Services Limited (as of Nov 11, 2026): return on equity 10.8%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is MEDPLUS from its 52-week high?
Medplus Health Services Limited trades at ₹618.60, about 35% below its 52-week high of ₹953.90 and 7% above the low of ₹579.90 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹707.67 is for.
Which stocks are comparable to Medplus Health Services Limited?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medplus Health Services Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹618.60, calculated fair value ₹707.67 (+14%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDPLUS calculated?
We run Medplus Health Services Limited through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹707.67 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Medplus Health Services Limited currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medplus Health Services Limited (MEDPLUS)?
The closing price on Nov 16, 2026 was ₹618.60. Our model-based fair value is ₹707.67, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medplus Health Services Limited right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Medplus Health Services Limited

How large is the market capitalisation of Medplus Health Services Limited (MEDPLUS)?
The market capitalisation of Medplus Health Services Limited is ₹74.3B (≈ $788M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medplus Health Services Limited (MEDPLUS)?
The price-to-sales ratio of Medplus Health Services Limited is 0.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medplus Health Services Limited (MEDPLUS)?
Earnings per share at Medplus Health Services Limited are ₹17.62 (price ÷ EPS = P/E 35.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medplus Health Services Limited (MEDPLUS)?
The net margin of Medplus Health Services Limited is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medplus Health Services Limited (MEDPLUS)?
The return on equity (ROE) of Medplus Health Services Limited is 10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medplus Health Services Limited (MEDPLUS)?
On an EBIT basis the return on assets of Medplus Health Services Limited is 15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medplus Health Services Limited (MEDPLUS)?
The operating margin of Medplus Health Services Limited is 5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medplus Health Services Limited (MEDPLUS)?
Revenue at Medplus Health Services Limited is growing 22.5% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medplus Health Services Limited (MEDPLUS)?
Earnings per share at Medplus Health Services Limited are growing 2.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medplus Health Services Limited (MEDPLUS) carry?
The net debt of Medplus Health Services Limited is ₹9.6B (fiscal year 2026, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medplus Health Services Limited in the live analysis

One click puts Medplus Health Services Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.